Established in 2020, DaXiang Technology is headquartered in Zhongguancun, Beijing, with research and development centers in Shanghai and Shenzhen. The company has built a complete matrix of organ chip products, covering multiple chip models such as liver, heart, and tumor, and has served more than 50 well-known pharmaceutical companies and research institutions at home and abroad. The core team is composed of returnee scientists from top universities such as Harvard and MIT, who have applied for more than 40 patents and participated in the development of industry standards. In 2022, nearly 100 million yuan of Series A financing will be completed, with investors including top institutions such as Sequoia Capital and Hillhouse Capital.

In 2023, DaXiang Technology achieved a commercial breakthrough: the first commercial organ chip product obtained CE certification from the European Union, and reached long-term cooperation with pharmaceutical companies such as Pfizer and Hengrui. The company is expanding its GMP level production base and expects to increase production capacity by 300% by 2024. After recently completing a Series B financing of 200 million yuan, DaXiang Technology is accelerating its layout of intelligent organ cultivation systems and AI data analysis platforms. It plans to promote the launch of 3-5 innovative chip products in the next three years and expand into the European and American markets, creating a leading global provider of organ chip solutions.